We tested the hypothesis that a single nucleotide polymorphism (SNP) located near the interleukin-28B gene is associated with the control of hepatitis C virus and HIV-1 replication in elite controllers/ suppressors. We show here that the protective genotype is not overrepresented in elite controllers/ suppressors compared with HIV-1-seronegative patients and HIV-1-infected patients with viral loads more than 10 000 copies/ml. Thus, it appears that this SNP is not associated with the elite control of HIV-1 infection.
The mechanisms involved in the control of hepatitis C virus (HCV) and HIV-1 infection remain unclear. The C/C genotype of a single nucleotide polymorphism (SNP) near the interleukin À28B (IL28B) gene has recently been associated with successful treatment [1, 2] and spontaneous clearance [3] of HCV infection. Although HIV-1 is not spontaneously cleared, viral replication is controlled to a level below the limit of detection by commercial assays in a cohort of patients known as elite controllers/suppressors [4] [5] [6] . A recent study has shown that elite controllers/suppressors are also more likely to clear HCV infection [7] , suggesting that common mechanisms may be involved in the control of the two polymorphic RNA viruses. IL28B encodes a type III interferon, which may suggest a role for innate immunity in HCV clearance. Such an innate immune response could potentially be involved in the control of other viruses including HIV-1. A recent study has documented that, in primary infection, elite controllers/ suppressors have peak viral loads that are 1-2 logs lower than that typically seen in patients who develop progressive disease [8] . Peak viremia precedes the development of the adaptive HIV-specific immune response, thus a strong innate immune response may be involved in the early control of HIV-1 replication in elite controllers/suppressors. Although it has recently been shown that the protective IL28B genotype does not affect the rate of CD4 þ T-cell decline in HIV-1-infected patients [9] , it is not known whether it plays a role in the elite control of HIV-1 replication. We, thus, examined the IL28B SNP in a well characterized cohort of 25 African-American elite controllers/suppressors, of whom 13 were seropositive for HCV. We hypothesized that the protective C/C allele would be overrepresented in this cohort compared with a cohort of patients with progressive HIV-1 disease if this SNP played a role in the elite suppression of HIV-1 replication.
HCV status was determined for all patients. A thirdgeneration enzyme immunoassay was used to determine the antibody status and quantitative HCV-RNA level was determined on all HCV-seropositive patients (Roche COBAS TaqMan 1.0 assay, Roche Molecular Systems, Branchburg, New Jersey, USA) with a limit of detection of 35 IU/ml). Liver disease stage was determined by histologic evaluation. Liver biopsy specimens were read by a single pathologist and staged/graded according to the METAVIR scoring system. Genotyping for IL28B was performed as previously described [3] .
Of 25 African-American elite controllers/suppressors in our cohort, 13 were HCV seropositive. Five of these patients had no detectable HCV-RNA, which was confirmed by repeat testing (Table 1) . A recent study has shown a higher rate of HCV clearance in elite controllers/suppressors than in HCV-monoinfected patients and in co-infected patients with progressive HIV-1 disease [7] . The clearance rate in our cohort (five of 13 HCV-seropositive elite controllers/suppressors or 38.5%) is similar to that seen by Sajadi et al. [7] and significantly higher than the rate of HCV clearance in a large study of African-American patients. In the remaining eight patients, a broad range of HCV-RNA levels was observed. The magnitude of HCV-RNA viremia was relatively low (<200 000 IU/ml) in three persons, but was high (>1 000 000 IU/ml) in the other five ( Table 1 ). Among the elite controller/suppressor patients with chronic HCV infection, serum alanine aminotransferase levels were modestly elevated (34-83 U/l /l), consistent with liver inflammation. Histologic evaluation was performed in six viremic patients, of whom one (elite controller/suppressor 4) had established cirrhosis. Interestingly, the human leukocyte antigen-B Ã 57 (HLA-B Ã 57) allele has been implicated in the control of HIV-1 [4] and HCV infection [10] and is clearly overrepresented in our cohort compared with the general African-American population [11] . Three of the five elite controllers/suppressors who cleared HCV viremia in our cohort were HLA-B Ã 57-positive, but several HLA-B Ã 57 patients also had very high HCV-RNA levels ( Table 1) . Taken together, the broad spectrum of liver disease seen in our cohort strongly suggests that elite Table 1 . Clinical characteristics and interleukin-28B genotype in a cohort of 25 African-American elite controllers/suppressors. control of HIV-1 does not necessarily lead to control of HCV infection.
We next determined the frequency of the protective C/C genotype in HCV-positive and HCV-negative patients in our cohort. Two of five patients who cleared HCV infection were positive for the C/C IL28B genotype. This is consistent with studies finding that this genotype is overrepresented in patients who clear HCV [3] . In order to determine whether this genotype also played a role in the control of HIV-1 replication, we looked at the frequency in the entire cohort and compared it with the frequency seen in HIV-1-positive and HIV- [3] ). This lack of overrepresentation of the protective C/C genotype in elite controllers/suppressors compared with HIV-1infected patients with substantial levels of HIV-1 viremia suggests that the IL28B SNP does not play a significant role in the elite control of HIV-1 replication.
Overall, our findings suggest that, although the protective IL28B allele contributes to the clearance of HCV infection in HIV-1-coinfected elite controllers/suppressors, it does not contribute to the control of HIV-1 infection in African-Americans. However, as most injection drug users acquire HCV infection much earlier than they became seropositive for HIV-1 [12] , it is possible that the sequence of viral infection plays a role in the IL28B-mediated control of viruses. Further studies are needed to elucidate the mechanisms by which IL28B contributes to the control of HCV infection, but not to HIV infection. 18) , we tested the hypothesis that drug-gene interaction may explain the highly variable drug interactions. Two-way analysis of variance revealed a significant interaction between CYP2B6 516G!T polymorphism and rifampin-containing therapy, suggesting that efavirenz dose adjustment may need to be individualized on the basis of the patient's genotype.
Efavirenz-based antiretroviral regimen is preferred during rifampin-containing antituberculous therapy. The adult fixed dose of 600 mg per day is associated with wide interindividual variability in plasma concentrations, as well as clinical outcome [1] [2] [3] . The variability in efavirenz concentrations is even greater during coadministration with rifampin or rifampin-containing antituberculous therapy [4] [5] [6] , suggesting a variable degree of drug-drug interaction. Among healthy volunteers, rifampin caused a significant reduction in efavirenz area under the curve (AUC) in 10 volunteers, but two volunteers had higher AUC on than off rifampin [4] . In HIV/tuberculosis (TB)-coinfected patients, the change in efavirenz AUC with concomitant rifampin administration ranged from À65% to þ37% in one study [7] . Efavirenz is primarily metabolized by hepatic CYP2B6, with some contributions from CYP3A4/5 [8] , CYP2A6 [9] , and UGT2B7 enzymes [10] . The lack of induction of efavirenz metabolism by rifampin in some individuals is contrary to the expected effect of rifampin on CYP2B6 activity [11] .
A bimodal effect of rifampin-containing therapy on efavirenz plasma concentrations has also been reported, with paradoxically higher concentrations with antituberculous therapy in the patients who appeared to be slow efavirenz metabolizers (based on phenotype only, as enzyme genotyping was not done) [5, 12] . Also, some HIV/TB-coinfected patients have required decreased efavirenz doses and/or discontinuation during rifampincontaining therapy because of severe toxicities associated with elevated efavirenz concentrations [13, 14] .
Elevations of efavirenz plasma concentration with rifampin-containing therapy that occur predominantly in persons with slow metabolizing phenotype suggest the possibility of a genotype-dependent drug-drug interaction. In this study, we investigated the potential for such an interaction between rifampin-containing antituberculous therapy and CYP2B6 516G!T polymorphism using data from a pharmacokinetic study conducted previously. The characteristics of the patients and results of the primary analysis are reported elsewhere [15] . All patients received efavirenz 600 mg per day with didanosine and lamivudine, and pharmacokinetic sampling was performed on day 28 of therapy. Antiretroviral therapy was initiated within 2-8 weeks of antituberculous therapy in coinfected patients and only those on concurrent therapy at the time of pharmacokinetic sampling were included in this analysis. The study was approved by the Institutional Review Board of the Nogouchi Memorial Institute for Medical Research, Ghana. Informed written consent was obtained from all patients.
Pharmacokinetic samples were drawn approximately 12 h after the efavirenz dose was taken. Efavirenz plasma concentrations were measured using a validated highperformance liquid chromatography/ultraviolet method [16] . Volunteers were genotyped for CYP2B6 c.516G!T (Q172H and rs3745274) using the fluorometric 5'-nuclease genotyping assay (Applied Biosystems, Foster City, California, USA). Two-way analysis of variance (ANOVA), which incorporates an interaction model, was used to investigate the effects of CYP2B6 516G!T polymorphism and rifampin-containing TB therapy. As in previous studies [15, 17] , concentration data were not normally distributed and so they were logtransformed prior to analysis. In instances where the ANOVA indicated a significant effect (P < 0.05), posthoc multiple pairwise comparison testing was performed using the Student-Newman-Keuls method to identify groups that were significantly different from each other.
The analysis included 38 HIV-infected patients on efavirenz-based therapy and 18 HIV/TB-coinfected patients on efavirenz-based and rifampin-containing antituberculous therapies. Concentration data from individual volunteers categorized by CYP2B6 516G!T genotype and type of therapy are shown in Fig. 1 . The two-way ANOVA revealed a statistically significant effect of CYP2B6 516 genotype on efavirenz plasma concentrations, as well as an interaction between CYP2B6 516G!T genotype and the antituberculous therapy (P < 0.001 for CYP2B6 516G!T polymorphism; P ¼ 0.089 for rifampin-containing therapy; and P ¼ 0.022 for interaction). Post-hoc pairwise analysis showed that patients with CYP2B6 516TT genotype who were receiving concurrent therapy had a significantly higher geometric mean efavirenz concentration than those on only antiretroviral therapy (14689 vs. 6012 ng/ml, respectively; P ¼ 0.006) ( Fig. 1) . Patients with CYP2B6 516GT genotype on concurrent antituberculous therapy had a slightly higher geometric mean efavirenz concentration than those on HAART only (1901 vs. 1778 ng/ml) and the patients with the CYP2B6 516GG genotype on antituberculous therapy had a lower geometric mean efavirenz concentrations than those with the CYP2B6 516GG genotype on HAART only (1291 vs. 1552 ng/ml), but these latter differences between therapeutic groups did not achieve statistical significance (P > 0.05).
As a CYP2B6 enzyme inducer, rifampin coadministration would be expected to enhance efavirenz clearance and reduce plasma levels. However, in this study, we found that the patients with CYP2B6 516TT genotype and receiving concomitant antituberculous therapy had higher efavirenz plasma concentrations than those volunteers with the same genotype, but not receiving antituberculous therapy. These findings are consistent with previous reports of elevated efavirenz concentration with rifampin-containing antituberculous therapy in HIV/TB-coinfected patients who appeared to have slow metabolizing phenotype, as genotyping was not done [5, 12, 14] . The paradoxical effect of antituberculous therapy in this study may be due to increased susceptibility of the CYP2B6 (172-histidine) variant allozyme (resulting from the c.516G!T polymorphism) to inhibition by one (or more) of the antituberculous drugs as compared with the reference CYP2B6 (172glutamine) enzyme. Alternately, efavirenz metabolism may be inhibited by effects on the non-CYP2B6 accessory pathways leading to higher efavirenz concentrations. CYP2A6-mediated 7-hydroxylation is identified as an important alternate pathway in the metabolism of efavirenz [9] and may be the major pathway for efavirenz clearance in CYP2B6 slow metabolizers [18] . Thus, inhibition of CYP2A6 by one (or more) of the antituberculous drugs could explain the higher concentrations. Studies are needed to determine the mechanism by which addition of the standard four-drug antituberculous therapy causes higher efavirenz concentrations in CYP2B6 slow metabolizers.
Our study has some limitations. First, the sample size is small and the lack of significant effect of antituberculous therapy on efavirenz concentrations in the CYP2B6 516GG and the CYP2B6 516GT genotype groups should be interpreted with caution. Second, the study compares two different patient populations and the differences seen in the CYP2B6 516TT genotype group could be due to population differences. However, our observation is supported by previous studies that showed paradoxically higher efavirenz concentrations during antituberculous therapy in the patients who appeared to be slow efavirenz metabolizers [5, 12] . If our results are confirmed in larger studies, CYP2B6 genotyping could inform rational decisions about efavirenz dosing or alternate therapy in HIV/TB-coinfected patients. 
